A Poor-quality Generic Drug for the Treatment of Visceral Leishmaniasis: A Case Report and Appeal
(2012; 4 pages)

Abstract

A generic miltefosine pharmaceutical product containing no active pharmaceutical ingredient for the treatment of visceral leishmaniasis emerged in Bangladesh for use in the national elimination programme. Poor-quality drugs for the treatment of this fatal neglected tropical disease are life-threatening for the vulnerable patients using them but also have a devastating impact on public health and elimination programmes targeting this disease. National drug regulators should take responsibility and ensure without any concessions that procured drugs for neglected tropical diseases, either innovator or generic, adhere to international standards for drug quality and safety.

 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014